
Boston Scientific (NYSE: BSX)
Boston Scientific Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Boston Scientific Company Info
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Urology and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.
News & Analysis
Best Medical Device Stocks to Buy for 2024
What Companies Does Johnson & Johnson Own?
What Is Convertible Preferred Stock?
These Are Billionaires’ Favorite Healthcare Stocks
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
This Medical Device Maker Will Be Well Positioned Post COVID
The pandemic is only a temporary setback for this diversified global manufacturer of medical devices.
3 Top Healthcare Stocks to Buy in August
New products mean solid revenue may be ahead for these companies.
Is Boston Scientific Stock a Buy?
Newly released products will drive revenue growth, but will they benefit shareholders?
Why These Top Medical Device Stocks Have Fallen by Double Digits So Far in 2020
High demand for a single product can't sustain an industry.
Valuation
Earnings Transcripts
Boston Scientific (BSX) Q2 2022 Earnings Call Transcript
BSX earnings call for the period ending June 30, 2022.
Boston Scientific (BSX) Q1 2022 Earnings Call Transcript
BSX earnings call for the period ending March 31, 2022.
Boston Scientific (BSX) Q4 2021 Earnings Call Transcript
BSX earnings call for the period ending December 31, 2021.
Boston Scientific Corp (BSX) Q3 2021 Earnings Call Transcript
BSX earnings call for the period ending September 30, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.